Switch theme
Sign up to access all valuation multiples
ODI Pharma AB is a provider of medicinal cannabis. It offers its products to pharmacies, specialty clinics, and hospitals.
2019
1
Last FY Revenue $2.3M
Last FY EBITDA $0.1M
$2.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, ODI Pharma achieved revenue of $2.3M and an EBITDA of $0.1M.
ODI Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ODI Pharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $2.3M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.5M | XXX | XXX | XXX |
| Gross Margin | XXX | 21% | XXX | XXX | XXX |
| EBITDA | XXX | $0.1M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 2% | XXX | XXX | XXX |
| EBIT | XXX | $45K | XXX | XXX | XXX |
| EBIT Margin | XXX | 2% | XXX | XXX | XXX |
| Net Profit | XXX | -$0.1M | XXX | XXX | XXX |
| Net Margin | XXX | -3% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, ODI Pharma's stock price is SEK 2 (or $0).
ODI Pharma has current market cap of SEK 24.7M (or $2.6M), and EV of SEK 22.7M (or $2.4M).
See ODI Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.4M | $2.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, ODI Pharma has market cap of $2.6M and EV of $2.4M.
ODI Pharma's trades at 2.0x EV/Revenue multiple, and -7.2x EV/EBITDA.
Equity research analysts estimate ODI Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ODI Pharma's P/E ratio is not available.
See valuation multiples for ODI Pharma and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.6M | XXX | $2.6M | XXX | XXX | XXX |
| EV (current) | $2.4M | XXX | $2.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -7.2x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -7.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -6.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialODI Pharma's revenue per employee in the last FY averaged $2.3M, while opex per employee averaged $0.4M for the same period.
ODI Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ODI Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ODI Pharma and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ODI Pharma acquired XXX companies to date.
Last acquisition by ODI Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . ODI Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was ODI Pharma founded? | ODI Pharma was founded in 2019. |
| Where is ODI Pharma headquartered? | ODI Pharma is headquartered in Sweden. |
| How many employees does ODI Pharma have? | As of today, ODI Pharma has 1 employees. |
| Is ODI Pharma publicy listed? | Yes, ODI Pharma is a public company listed on SAT. |
| What is the stock symbol of ODI Pharma? | ODI Pharma trades under ODI ticker. |
| When did ODI Pharma go public? | ODI Pharma went public in 2020. |
| Who are competitors of ODI Pharma? | Similar companies to ODI Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of ODI Pharma? | ODI Pharma's current market cap is $2.6M |
| Is ODI Pharma profitable? | Yes, ODI Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
